Efficacy and Safety of Cerebrolysin in Hemorrhagic Stroke Patients
Author Information
Author(s): Bajenaru O, Tiu C, Moessler H, Antochi F, Muresanu D, Popescu BO, Novak P
Primary Institution: University Hospital Bucharest
Hypothesis
The study aims to investigate the efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke.
Conclusion
Cerebrolysin treatment is safe and well tolerated in patients with hemorrhagic stroke, although no statistically significant efficacy was demonstrated.
Supporting Evidence
- 96 out of 100 randomized patients completed the study.
- The treatment was administered for 10 days with daily infusions.
- Safety evaluations showed no significant toxic effects from Cerebrolysin.
- Adverse events were comparable between the Cerebrolysin and placebo groups.
- Statistical analysis indicated no significant differences in efficacy measures.
Takeaway
This study tested a medicine called Cerebrolysin to see if it helps people who have a type of stroke called hemorrhagic stroke, and it found that the medicine is safe to use.
Methodology
The study was a prospective, randomized, double-blind, placebo-controlled trial with 100 patients, assessing efficacy through various neurological scales over 21 days.
Limitations
The study did not find statistically significant group effects, and a larger sample size may be needed to provide clearer evidence of efficacy.
Participant Demographics
The study included 100 patients aged 40 to 85, with 62% male and 28% female participants, average age 65.
Want to read the original?
Access the complete publication on the publisher's website